Advertisement
UK markets close in 8 hours 13 minutes
  • FTSE 100

    8,290.99
    +77.50 (+0.94%)
     
  • FTSE 250

    20,300.46
    +135.92 (+0.67%)
     
  • AIM

    771.75
    +0.22 (+0.03%)
     
  • GBP/EUR

    1.1648
    -0.0012 (-0.10%)
     
  • GBP/USD

    1.2539
    -0.0025 (-0.20%)
     
  • Bitcoin GBP

    50,758.71
    -483.75 (-0.94%)
     
  • CMC Crypto 200

    1,367.60
    +2.47 (+0.18%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • DOW

    38,852.27
    +176.59 (+0.46%)
     
  • CRUDE OIL

    78.47
    -0.01 (-0.01%)
     
  • GOLD FUTURES

    2,327.60
    -3.60 (-0.15%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • HANG SENG

    18,482.30
    -96.00 (-0.52%)
     
  • DAX

    18,246.84
    +71.63 (+0.39%)
     
  • CAC 40

    8,035.29
    +38.65 (+0.48%)
     

The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin

The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin

In the first quarter, Novo Nordisk’s (NVO) premix insulin generated net revenues of 2.64 billion Danish kroner compared to 2.86 billion Danish kroner in the first quarter of 2017, which reflected an ~8.0% YoY (year-over-year) decline.